(S)-tert-butyl-3-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate | 1258558-27-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (S)-tert-butyl-3-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate
• 英文别名: tert-butyl (S)-3-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate；1-Piperidinecarboxylic acid, 3-(4-amino-1H-pyrazol-1-yl)-, 1,1-dimethylethyl ester, (3S)-；tert-butyl (3S)-3-(4-aminopyrazol-1-yl)piperidine-1-carboxylate
• CAS: 1258558-27-8
• 化学式: C₁₃H₂₂N₄O₂
• 分子量: 266.343
• InChiKey: GTEFUHRBXXWZIJ-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  73.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• PYRIMIDINE INHIBITORS OF KINASES
  申请人：Curtin Michael

  公开号：US20100317680A1

  公开（公告）日：2010-12-16

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A 1 , A 2 , A 3 , A 4 , X and Y are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as aurora and KDR.

  本发明涉及式(I)的化合物或药用可接受的盐，其中A1、A2、A3、A4、X和Y在描述中有定义。本发明还涉及制备所述化合物的方法，以及含有所述化合物的组合物，用于抑制aurora和KDR等激酶。
• [EN] NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF<br/>[FR] NOUVEAUX COMPOSÉS PYRIMIDINES ET PYRIDINES ET LEUR UTILISATION
  申请人：HUTCHISON MEDIPHARMA LTD

  公开号：WO2014139145A1

  公开（公告）日：2014-09-18

  Provided are novel pyrimidine and pyridine compounds of formula (I) or a pharmaceutical acceptable salt thereof, pharmaceutical compositions containing them, a process for preparing them, and their use in therapy of a disease responsive to inhibition of FGFR, for example, cancer.

  提供了式(I)的新型嘧啶和吡啶化合物或其药用可接受的盐，含有它们的药物组合物，制备它们的方法，以及它们在对抗对FGFR抑制敏感的疾病（例如癌症）的治疗中的用途。
• [EN] NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE<br/>[FR] NOUVEAUX COMPOSÉS DE PYRIMIDINE ET DE PYRIDINE ET LEUR UTILISATION
  申请人：HUTCHISON MEDIPHARMA LTD

  公开号：WO2014139465A1

  公开（公告）日：2014-09-18

  The present invention relates to novel pyrimidine and pyridine compounds of formula (I) or a pharmaceutical acceptable salt thereof, wherein R1, R2, R3, R4, R5, X, Y and G are as defined in the description, to pharmaceutical compositions containing them, a process for preparing them, and their use in therapy of a disease responsive to inhibition of FGFR, for example, cancer.

  本发明涉及通式(I)的新型嘧啶和吡啶化合物或其药学上可接受的盐，其中R1、R2、R3、R4、R5、X、Y和G如说明书中所定义，涉及含有它们的药物组合物、制备它们的方法以及它们在治疗对FGFR抑制有反应的疾病，例如癌症中的用途。
• NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE
  申请人：HUTCHISON MEDIPHARMA LIMITED

  公开号：US20160024021A1

  公开（公告）日：2016-01-28

  The present invention relates to novel pyrimidine and pyridine compounds of formula (I) or a pharmaceutical acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, Y and G are as defined in the description, to pharmaceutical compositions containing them, a process for preparing them, and their use in therapy of a disease responsive to inhibition of FGFR, for example, cancer.

  本发明涉及公式（I）的新型嘧啶和吡啶化合物，或其药物可接受的盐，其中R1，R2，R3，R4，R5，X，Y和G如描述中所定义，以及包含它们的制药组合物，制备它们的过程以及它们在对抗需要抑制FGFR的疾病治疗中的用途，例如癌症。
• NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF
  申请人：HUTCHISON MEDIPHARMA LIMITED

  公开号：US20160052926A1

  公开（公告）日：2016-02-25

  The present invention relates to novel pyrimidine and pyridine compounds of formula (I) or a pharmaceutical acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, Y and G are as defined in the description, to pharmaceutical compositions containing them, a process for preparing them, and their use in therapy of a disease responsive to inhibition of FGFR, for example, cancer.

  本发明涉及一种新的嘧啶和吡啶化合物，其化学式为（I）或其药物可接受的盐，其中R1、R2、R3、R4、R5、X、Y和G的定义如描述中所述，以及含有它们的制药组合物，制备它们的过程，以及它们在治疗对FGFR抑制有反应的疾病，例如癌症中的用途。